Results 101 to 110 of about 1,763 (188)
BACKGROUND: This study aims to evaluate the effectiveness of radiotherapy (RT) in stabilizing oligoprogressive disease (OPD) in melanoma patients undergoing immunotherapy.
Martin Palkovsky +7 more
doaj +1 more source
Background During the systemic treatment of patients with non‐small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention.
Daisuke Morinaga +16 more
doaj +1 more source
Imaging as a Surgical Decision System in Modern Gynecologic Oncology
Imaging traditionally supports gynecologic oncology through diagnosis, staging, and estimation of resectability. Contemporary treatment, however, requires longitudinal decisions about which lesion matters, when local intervention is justified, and which ...
Angel Yordanov +5 more
doaj +1 more source
IBS01.02 Strategies Treatment After Oligoprogression [PDF]
F. Cappuzzo, L. Landi
openaire +1 more source
Purpose To assess the association between colorectal cancer (CRC) histology, dose, and local failure (LF) after stereotactic ablative radiation therapy (SABR) for pulmonary metastases, and to describe subsequent cancer progression, change of systemic ...
Soliman, Hany +17 more
core +1 more source
Oligometastatic NSCLC: Current Perspectives and Future Challenges [PDF]
Oligometastatic non-small cell lung cancer (NSCLC) represents a separate entity with a different biology and prognosis compared to stage IV NSCLC. Challenges range from the very definition of oligometastatic disease to the timing and techniques of local ...
Zanchetta C. +5 more
core +1 more source
Trial Registration: ClinicalTrials.gov identifier ...
David Sánchez García +6 more
doaj +1 more source
Background: Hepatocellular carcinoma (HCC) is a highly aggressive cancer with a paucity of efficacious treatment options, particularly in advanced stages following first-line systemic therapy (FLST).
Haohua Wang +10 more
doaj +1 more source
External validation of a genomic signature for oligometastatic non-small cell lung cancer
Objective: We previously presented a genomic signature predictive of both oligometastatic disease state and oligoprogression in patients with brain metastases.
Xing, Fei +17 more
core

